Rb and p53 gene deletions in lung adenocarcinomas from irradiated and control mice

Radiation Research

Volumn 148, Issue 1, 1997, Pages 81-89

  Zhang, Yueru ^a   Woloschak, Gayle E ^a  

^a ARGONNE NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; RETINOBLASTOMA PROTEIN; VIRUS T ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GAMMA RADIATION; GENE DELETION; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ANIMALS; BLOTTING, SOUTHERN; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; GAMMA RAYS; GENE DELETION; GENES, P53; GENES, RETINOBLASTOMA; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS, RADIATION-INDUCED; NEUTRONS;

EID: 0030981468     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.2307/3579541     Document Type: Article

References (44)

1. D. P. Lane, p53, guardian of the genome. Nature 358, 15-16 (1992). [News]
2. E. R. Fearon and B. Vogelstein, A genetic model for colorectal tumorigenesis. Cell 61, 759-767 (1990).
3. J. C. Barrett and M. Anderson, Molecular mechanisms of carcinogenesis in humans and rodents. Mol. Carcinogen. 7, 1-13 (1993).
4. M. Hollstein, D. Sidransky, B. Vogelstein and C. C. Harris, p53 mutations in human cancers. Science 253, 49-53 (1991).
5. C. C. Harris, p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 262, 1980-1981 (1993).
6. G. Selivanova and K. G. Wiman, p53: a cell cycle regulator activated by DNA damage. Adv. Cancer Res. 66, 143-177 (1995).
7. M. F. Hansen and W. F. Cavenee, Retinoblastoma and the progression of tumor genetics. Trends Genet. 4, 125-128 (1988).
8. R. S. Sparkes, The genetics of retinoblastoma. Biochim. Biophys. Acta 780, 95-118 (1985).
9. W. F. Benedict, A. L. Murphree, A. Banerjee, C. A. Spina, M. C. Sparkes and R. S. Sparkes, Patient with 13 chromosome deletion: evidence that the retinoblastoma gene is a recessive cancer gene. Science 219, 973-975 (1983).
10. J. Toguchida, K. Ishizaki, M. Sasaki, M. Ikenaga, M. Sugimoto, Y. Kotokura and T. Yamamoto, Chromosomal reorganization for the expression of recessive mutation of retinoblastoma susceptibility gene in the development of osteosarcoma. Cancer Res. 48, 3939-3943 (1988).
11. M. Oren, W. Maltzman and A. J. Levine, Post-translational regulation of the 54k cellular tumor antigen in normal and transformed cells. Mol. Cell. Biol. 1, 101-110 (1981).
12. J. V. Gannon, R. Greaves, R. Iggo and D. P. Lane, Activation mutations in p53 produce a common conformational effect: A monoclonal-antibody specific for the mutant form. EMBO J. 12, 1021-1028 (1990).
13. J. W. Harper, G. R. Adami, N. Wei, K. Keyomarsi and S. J. Elledge, The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinase. Cell 75, 805-816 (1993).
14. W. S. El-Deiry, T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. Trent, D. Lin, W. E. Mercer, K. W. Kinzler and B. Vogelstein, WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825 (1993).
15. Y. Xiong, G. J. Hannon, H. Zhang, D. Casso, R. Kobayashi and D. Beach, p21 is a universal inhibitor of cyclin kinase. Nature 366, 701-704 (1993).
16. D. E. Thompson, K. Mabuchi, E. Ron, M. Soda, M. Tokunaga, S. Ochikubo, S. Sugimoto, T. Ikeda, M. Terasaki, S. Izumi and D. L. Preston, Cancer incidence in atomic bomb survivors: Part II. Solid tumors, 1958-1987. Radiat. Res. 137, S17-S67 (1994).
17. M. Charles, R. Cox, D. Goodhead and A. Wilson, The effects of high-LET radiation at low doses/dose rates. Int. J. Radiat. Biol. 58, 859-885 (1990). [Meeting report with extended abstracts]
18. R. L. Ullrich, Tumor induction in BALB/c mice after fractionated or protracted exposures to fission-spectrum neutrons. Radiat. Res. 97, 587-597 (1984).
19. 2. Radiat. Res. 111, 201-224 (1987).
20. D. Grahn, B. J. Wright, B. A. Carnes, F. S. Williamson and C. Fox, Studies of Acute and Chronic Radiation Injury at the Biological and Medical Research Division, Argonne National Laboratory, 1970-1992: The JANUS Program Survival and Pathology Data. Report ANL-95/3, Argonne National Laboratory, Argonne, IL, 1995.
21. D. Grahn, J. F. Thomson and B. Carnes, Relative Biological Effectiveness (RBE) of Fission Neutrons and Gamma Rays at Occupational Exposure Levels: Vol. III. Studies on the Gross Microscopic Pathology Observed at Death of Mice Exposed to 60 Equal Once-Weekly Doses of Fission Neutrons and Gamma Rays. Report ANL-86-33, Vol. III (NUREG/CR 4704, Vol. II), Argonne National Laboratory, Argonne, IL, 1990.
22. 1 mouse. Radiat. Res. 129, 19-36 (1992).
23. M. E. Churchill, M. A. Gemmell and G. E. Woloschak, Detection of retinoblastoma gene deletions in spontaneous and radiation-induced mouse lung adenocarcinomas by polymerase chain reaction. Radiat. Res. 137, 310-316 (1994).
24. W. P. Bennett, M. C. Hollstein, R. A. Metcalf, J. A. Welsh, A. He, S. M. Zhu, I. Kusters, J. H. Resau, B. F. Trump, D. P. Lane and C. C. Harris, p53 mutations and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res. 52, 6092-6097 (1992).
25. R. Bernards, G. M. Schackleford, M. R. Gerber, J. M. Horowitz, S. H. Friend, M. Schartl, E. Bogenmann, J. M. Rapaport, T. McGee, T. P. Dryja and R. A. Weinberg, Structure and expression of the murine retinoblastoma gene and encoded protein. Proc. Natl. Acad. Sci. USA 86, 6474-6478 (1989).
26. 2-microglobulin genes. Cell 29, 661-669 (1982).
27. J. H. Zar, Biostatistical Analysis, 2nd ed. Prentice-Hall, Englewood Cliffs, NJ, 1984.
28. C. K. Hill, B. A. Carnes, A. Han and M. M. Elkind, Neoplastic transformation is enhanced by multiple low doses of fission-spectrum neutrons. Radiat. Res. 102, 404-410 (1995).
29. R. C. Miller, G. Randers-Pehrson, L. Heiber, S. A. Marino, M. Richards and E. J. Hall, The inverse dose-rate effect for oncogenic transformation by charged particles is dependent on linear energy transfer. Radiat. Res. 133, 360-364 (1993).
30. D. J. Brenner, E. J. Hall, G. Randers-Pehrson and R. C. Miller, Mechanistic considerations on the dose-rate/LET dependence of oncogenic transformation by ionizing radiations. Radiat. Res. 133, 365-369 (1993).
31. J. Thacker, Radiation-induced mutation in mammalian cells at low doses and dose rates. In Advances in Radiation Biology, Vol. 16 (O. F. Nygaard, W. K. Sinclair and J. T. Lett, Eds.), pp. 77-124. Academic Press, San Diego, 1992.
32. D. T. Goodhead, Track structure considerations in low dose and low dose rate effects of ionizing radiation. In Advances in Radiation Biology, Vol. 16 (O. F. Nygaard, W. K. Sinclair and J. T. Lett, Eds.), pp. 7-45. Academic Press, San Diego, 1992.
33. D. T. Goodhead, Spatial and temporal distribution of energy. Health Phys. 55, 231-240 (1988).
34. A. Wambersie, G. W. Barendsen and N. Breteau, Overview and prospects of the application of fast neutrons in cancer therapy. J. Eur. Radiother. 5, 248-264 (1984).
35. J. Thacker, The molecular nature of mutations in cultured mammalian cells: a review. Mutat. Res. 150, 431-442 (1985).
36. 125I decay and X-ray-induced HPRT mutants in CHO cells. Int. J. Radiat. Biol. 51, 193-199 (1987).
37. W. G. Kaelin, D. C. Pallas, J. A. DeCaprio, F. J. Kaye and D. M. Livingston, Identification of cellular proteins that can interact specifically with the T/E1A-binding region of the retinoblastoma gene product. Cell 64, 521-532 (1991).
38. J. W. Ludlow and G. R. Skuse, Tumor Suppressors, Involvement in Human Diseases, Viral Protein Interactions and Growth Regulation. R. G. Landes, Georgetown, TX, 1994.
39. J. Bartek, J. Bartkova, B. Vojtesek, Z. Staskova, J. Lukas, A. Rejthar, J. Kovarik, C. A. Midgley, J. V. Gannon and D. P. Lane, Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6, 1699-1703 (1991).
40. T. Paunesku, M. A. Gemmell, R. Crkvenjakov and G. E. Woloschak, A presumed B6 strain-specific p53 polymorphism is confined to a B6 cell line and is likely to represent a facilitating mutation. Mamm. Genome 5, 106-107 (1994).
41. H. Matsuyama, Y. Pan, E. A. Mahdy, P. U. Malmstrom, A. Hedrum, M. Uhlen, C. Busch, T. Hirano, G. Auer, B. Tribukait, K. Naito, P. Lichter, P. Ekman and U. S. R. Bergerheim, p53 deletion as a genetic marker in urothelial tumor by fluorescence in situ hybridization. Cancer Res. 54, 6057-6060 (1994).
42. G. Sauter, G. R. Deng, H. Moch, R. Kerschmann, K. Matsumura, S. Devries, T. George, J. Fuentes, P. Carroll, M. J. Mihatsch and F. M. Waldman, Physical deletion of the p53 gene in bladder-cancer: detection by fluorescence in-situ hybridization. Am. J. Pathol. 144, 756-766 (1984).
43. C. C. Hsia, A. M. Dibisceglie, D. E. Kleiner, M. Farshid and E. Tabor, Rb tumor suppressor gene expression in hepatocellular carcinomas from patients infected with the hepatitis-B virus. J. Med. Virol. 44, 67-73 (1994).
44. C. W. Miller, K. Simon, A. Also, K. Kok, J. Yokata, C. H. C. M. Buys, M. Terada and H. P. Koeffler, p53 mutations in human lung tumors. Cancer Res. 52, 1695-1698 (1992).